Graig Suvannavejh
Stock Analyst at Mizuho
(2.48)
# 2,386
Out of 4,915 analysts
157
Total ratings
49.17%
Success rate
-1.11%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Graig Suvannavejh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALEC Alector | Upgrades: Outperform | $2.5 → $3.5 | $1.49 | +134.90% | 5 | Jul 28, 2025 | |
| NMRA Neumora Therapeutics | Maintains: Outperform | $4 → $5 | $1.96 | +155.10% | 2 | Jul 16, 2025 | |
| ADVM Adverum Biotechnologies | Maintains: Outperform | $16 → $12 | $2.37 | +406.33% | 5 | Jun 26, 2025 | |
| ADAP Adaptimmune Therapeutics | Downgrades: Neutral | $1.5 → $0.5 | $0.08 | +522.67% | 3 | Jun 26, 2025 | |
| IMRX Immuneering | Maintains: Outperform | $8 → $10 | $3.44 | +190.70% | 2 | Jun 18, 2025 | |
| INSM Insmed | Maintains: Outperform | $96 → $110 | $107.28 | +2.54% | 10 | Jun 11, 2025 | |
| CRVS Corvus Pharmaceuticals | Maintains: Outperform | $12 → $11 | $4.19 | +162.84% | 3 | May 20, 2025 | |
| EYPT EyePoint Pharmaceuticals | Maintains: Outperform | $30 → $26 | $9.83 | +164.63% | 5 | May 16, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Outperform | $44 → $48 | $35.18 | +36.44% | 18 | May 15, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Neutral | $30 → $20 | $22.34 | -10.47% | 7 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $8 | $8.04 | -0.44% | 7 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $33 | $32.77 | +0.70% | 8 | Apr 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $212 → $216 | $101.38 | +113.06% | 21 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $7 → $7.6 | $2.40 | +216.67% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 | $9.27 | +698.27% | 1 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $5 → $0.5 | $0.38 | +31.58% | 3 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $44 → $49 | $59.97 | -18.29% | 6 | Jul 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $24.35 | +105.34% | 1 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $16 | $6.45 | +148.06% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $10 | $5.83 | +71.53% | 5 | Nov 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $64 | $1.31 | +4,785.50% | 8 | Aug 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $17 → $1 | $3.71 | -73.05% | 5 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $8.05 | +86.34% | 1 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $35 | $85.29 | -58.96% | 5 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $8 | $6.58 | +21.67% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $71 → $57 | $37.64 | +51.43% | 2 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $5 | $35.50 | -85.92% | 4 | Apr 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $7.35 | +362.59% | 1 | Jun 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $28 | $3.90 | +617.95% | 1 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $31 | $14.27 | +117.24% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $19 | $2.07 | +817.87% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $4.75 | $2.11 | +125.12% | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $36 | $14.58 | +146.91% | 2 | Nov 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $32.78 | - | 1 | Oct 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $37 | $0.81 | +4,479.77% | 1 | Oct 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $128 | $114.63 | +11.66% | 1 | Sep 14, 2020 |
Alector
Jul 28, 2025
Upgrades: Outperform
Price Target: $2.5 → $3.5
Current: $1.49
Upside: +134.90%
Neumora Therapeutics
Jul 16, 2025
Maintains: Outperform
Price Target: $4 → $5
Current: $1.96
Upside: +155.10%
Adverum Biotechnologies
Jun 26, 2025
Maintains: Outperform
Price Target: $16 → $12
Current: $2.37
Upside: +406.33%
Adaptimmune Therapeutics
Jun 26, 2025
Downgrades: Neutral
Price Target: $1.5 → $0.5
Current: $0.08
Upside: +522.67%
Immuneering
Jun 18, 2025
Maintains: Outperform
Price Target: $8 → $10
Current: $3.44
Upside: +190.70%
Insmed
Jun 11, 2025
Maintains: Outperform
Price Target: $96 → $110
Current: $107.28
Upside: +2.54%
Corvus Pharmaceuticals
May 20, 2025
Maintains: Outperform
Price Target: $12 → $11
Current: $4.19
Upside: +162.84%
EyePoint Pharmaceuticals
May 16, 2025
Maintains: Outperform
Price Target: $30 → $26
Current: $9.83
Upside: +164.63%
Harmony Biosciences Holdings
May 15, 2025
Maintains: Outperform
Price Target: $44 → $48
Current: $35.18
Upside: +36.44%
Apellis Pharmaceuticals
May 14, 2025
Maintains: Neutral
Price Target: $30 → $20
Current: $22.34
Upside: -10.47%
May 14, 2025
Maintains: Outperform
Price Target: $7 → $8
Current: $8.04
Upside: -0.44%
Apr 7, 2025
Maintains: Neutral
Price Target: $38 → $33
Current: $32.77
Upside: +0.70%
Mar 27, 2025
Maintains: Outperform
Price Target: $212 → $216
Current: $101.38
Upside: +113.06%
Nov 18, 2024
Upgrades: Buy
Price Target: $7 → $7.6
Current: $2.40
Upside: +216.67%
Sep 20, 2024
Reiterates: Outperform
Price Target: $74
Current: $9.27
Upside: +698.27%
Sep 19, 2024
Downgrades: Neutral
Price Target: $5 → $0.5
Current: $0.38
Upside: +31.58%
Jul 22, 2024
Maintains: Neutral
Price Target: $44 → $49
Current: $59.97
Upside: -18.29%
Jul 8, 2024
Initiates: Outperform
Price Target: $50
Current: $24.35
Upside: +105.34%
May 16, 2024
Maintains: Buy
Price Target: $14 → $16
Current: $6.45
Upside: +148.06%
Nov 27, 2023
Maintains: Buy
Price Target: $17 → $10
Current: $5.83
Upside: +71.53%
Aug 23, 2023
Reiterates: Neutral
Price Target: $64
Current: $1.31
Upside: +4,785.50%
Jun 5, 2023
Downgrades: Neutral
Price Target: $17 → $1
Current: $3.71
Upside: -73.05%
Mar 31, 2023
Initiates: Buy
Price Target: $15
Current: $8.05
Upside: +86.34%
Nov 10, 2022
Maintains: Buy
Price Target: $31 → $35
Current: $85.29
Upside: -58.96%
Nov 10, 2022
Maintains: Neutral
Price Target: $9 → $8
Current: $6.58
Upside: +21.67%
May 24, 2022
Maintains: Buy
Price Target: $71 → $57
Current: $37.64
Upside: +51.43%
Apr 19, 2022
Maintains: Sell
Price Target: $8 → $5
Current: $35.50
Upside: -85.92%
Jun 1, 2021
Initiates: Buy
Price Target: $34
Current: $7.35
Upside: +362.59%
Apr 20, 2021
Initiates: Neutral
Price Target: $28
Current: $3.90
Upside: +617.95%
Apr 19, 2021
Initiates: Neutral
Price Target: $31
Current: $14.27
Upside: +117.24%
Mar 2, 2021
Initiates: Sell
Price Target: $19
Current: $2.07
Upside: +817.87%
Nov 24, 2020
Initiates: Neutral
Price Target: $4.75
Current: $2.11
Upside: +125.12%
Nov 9, 2020
Upgrades: Buy
Price Target: $36
Current: $14.58
Upside: +146.91%
Oct 21, 2020
Downgrades: Sell
Price Target: n/a
Current: $32.78
Upside: -
Oct 20, 2020
Initiates: Neutral
Price Target: $37
Current: $0.81
Upside: +4,479.77%
Sep 14, 2020
Downgrades: Sell
Price Target: $128
Current: $114.63
Upside: +11.66%